DISCOUNT OPTIONSSCHEIN - NOVO NORDISK ADR B | Market Closed - Deutsche Boerse AG 18:53:44 16/07/2024 BST | ||
| 1.47 EUR | 0.00% |
|
| 1 month | -3.29% | ||
| 3 months | +31.25% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
More news
| Date | Price | Change |
|---|---|---|
| 16/07/24 | 1.47 | 0.00% |
| 15/07/24 | 1.47 | -1.34% |
| 12/07/24 | 1.49 | +3.47% |
| 11/07/24 | 1.44 | -3.36% |
| 10/07/24 | 1.49 | +1.36% |
Delayed Quote Deutsche Boerse AG
Last update July 16, 2024 at 06:53 pm
More quotesStatic data
| Product type | Exotic Products |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
Vontobel
|
| WKN | VM37Q9 |
| ISIN | DE000VM37Q99 |
| Date issued | 19/10/2023 |
| Strike | 110 $ |
| Maturity | 20/12/2024 (157 Days) |
| Parity | 10 : 1 |
| Emission price | 0.58 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 1.58 € |
|---|---|
| Lowest since issue | 0.47 € |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
970
DKK
Average target price
956.8
DKK
Spread / Average Target
-1.36%
- Stock Market
- Certificates
- Certificat
